Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

1/4 of a million people have applied to take part in a clinical trial with Richmond Pharmacology!

31
August 2006

View Articles

5th Annual Partnerships in Clinical Trials Congress (PCT) and Exhibition

15
August 2006

View Articles

Knowledge Transfer Partnership Sponsored by the Department of Trade & Industry (DTI)

4
July 2006

View Articles

Head of Data Management beats his personal best in the 2006 London Marathon

28
April 2006

View Articles

Statement from Dr. Jorg Taubel

16
March 2006

View Articles

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

22
December 2005

View Articles

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event